Biostem Technologies (NASDAQ:BSEM) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Biostem Technologies (NASDAQ:BSEM) to a sell rating in a report issued on Saturday morning,Wall Street Zen reports.

Separately, Weiss Ratings started coverage on Biostem Technologies in a report on Wednesday, August 19th. They issued a “sell (d-)” rating on the stock. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Biostem Technologies currently has a consensus rating of “Sell”.

Biostem Technologies Price Performance

Shares of Biostem Technologies stock opened at $3.71 on Friday. The company has a market capitalization of $66.22 million, a price-to-earnings ratio of -2.31 and a beta of 0.12. The stock’s 50-day simple moving average is $3.57 and its 200-day simple moving average is $4.46. Biostem Technologies has a 52 week low of $2.25 and a 52 week high of $8.40.

Biostem Technologies Company Profile

BioStem Technologies, Inc (NASDAQ: BSEM) is a biotechnology company focused on regenerative medicine and biologic tissue products. Through its operating businesses, the company develops, manufactures and distributes human tissue allografts intended to support wound care, surgical procedures and other regenerative applications.

Its product portfolio includes placental-tissue-based products, including amniotic membrane and related graft technologies. These products are designed for use by health-care professionals in applications such as wound management and tissue repair.